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Ab stract
In this paper we report the synthesis and biological evaluation of a new series of pyrazolo[1’,5’:1,6]pyrimido[4,5-
d]pyridazin-4(3H)-ones as human A1 adenosine receptor ligands. The tricyclic scaffold was modified at position 6 and
9 by introducing small alkyl chains and substituted phenyls. The most interesting compounds showed Ki for A1 in the
submicromolar range (0.105–0.244 μM) and the most interesting term (compound 4c) combined an appreciable affinity
for A1 (Ki = 0.132 μM) with a good selectivity toward A2A (43% inhibition at 10 μM) and A3 (46% inhibition at 10 μM).
Keywords: Adenosine receptors, A1 subtype, Ligands, Pyrazolo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones.
1. In tro duc tion
For several years, adenosine receptors have been
classified in four different subtypes, A1, A2A, A2B and A3
1.
All these receptors have been cloned from several species
and have been demonstrated to differ in their primary se-
quence, pharmacological effects, tissue distribution and
coupling to different G proteins. A1 and A3 subtypes, other
that modulate calcium levels through a Gq proteins, are
coupled to Gi proteins to inhibit adenyl cyclase. On the
contrary, A2A and A2B receptors are primary coupled to Gs
proteins and activate adenylyl cyclase causing, in turn, an
increase in intracellular cAMP production.2,3 The endoge-
nous ligand, adenosine, interacts with all the receptor
subtypes with different affinity and may elicit different ef-
fects at level of second messengers. The final effect indu-
ced by adenosine may differ in physiological and patholo-
gical conditions during which the expression levels of
each subtypes are regulated and obviously these effects
depend on the relative abundance of each receptor subty-
pes in specific tissues.
Ligand-binding properties of each adenosine recep-
tor are primarily dictated by amino acids in the transmem-
brane domains of the receptors. Studies have identified
certain amino acids conserved amongst adenosine recep-
tor subtypes that are critical for ligand recognition, as well
as additional residues that may differentiate between ago-
nist and antagonist ligands and between the different re-
ceptor subtypes.4
The potential therapeutic applications of compounds
able to bind these receptors have been investigated in re-
cent years.5,6 In particular antagonists for the A1 receptor
subtype may be useful for the treatment of central nervous
system pathologies such as Alzheimer’s and Parkinson’s
diseases,7 for the treatment of congestive heart failure due
to their diuretic and positive inotropic effects2,8 and for the
treatment of asthma since adenosine mediates broncho-
constriction and inflammation in the lung.9,10
A large number of nitrogen-containing polyheterocy-
cles as pyrido[2,3-d]pyrimidinediones11 (A), pyrimido[4,5-
b]indole (B),12 and triazinobenzimidazolones (C)13 have
been reported in literature as A1R antagonists (Figure 1).
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In a recent paper14 we reported the synthesis and bin-
ding activities at human cloned A1, A2A, A2B and A3 adeno-
sine receptors of a new series of compounds with pyrazo-
lo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones scaf-
fold (compound D, Figure 1). Some of these compounds
showed a good activity for hA1 adenosine subtypes, with
values of Ki in the submicromolar range and a good selec-
tivity versus other adenosine receptor subtypes14.
Selecting as lead the fluoroderivative 4a (Ki = 0.252
μM) from the previous series, we report here the results of
further modifications on the above scaffold at the level of
positions 6 and 9 by maintaining the benzyl group unc-
hanged at 3 necessary for A1 affinity and 4-F-phenyl at
position 1.
pound 5 was obtained starting from 4c by reduction of the
NO2 group with SnCl2.
Scheme 2 depicts the synthesis of the final com-
pound 10 which was obtained starting from the previously
described14 pyrazolopyrimido[4,5-d]pyridazinone 8,
through transformation into the corresponding 4-thione
derivative 9 with Lawesson’s reagent followed by alkyla-
tion at position 4 with benzyl chloride in standard condi-
tions.
2. 2. Phar ma co logy
All the final compounds were investigated in radioli-
gand binding studies to determine their affinities for human
A B C D
Figure 1: A1 receptor antagonists
2. Re sults and Dis cus sion
2. 1. Che mi stry
The final compounds 4-7 (4a14) were prepared follo-
wing a general synthetic procedure previously described
by us15 (Scheme 1).
Isoxazolo[3,4-d]-pyridazin-7(6H)-one 114 was con-
densed with the appropriate arylaldehydes (or N,N-di-
methylformammide dimethyl acetal for compound 2g) to
give the vinyl derivatives 2a-g (2a14) which treated with
hydrazine hydrate furnished intermediates 3a-g (3a14)
through the isoxazole opening and the following closure
to pyrazole16. Finally the cyclization to pyrazo-
lo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-one was car-
ried out in different conditions depending on the substi-
tuent at position 6.
For the 6-unsubstituted 4a-f, the ring closure was
performed with triethylorthoformate in anhydrous DMF
in the presence of catalytic amount of concentrated sulfu-
ric acid at room temperature, whereas compounds 6a-c
were obtained with the opportune anhydride under reflu-
xing conditions. Compound 7 was synthesized starting
from 4-amino-5-pyrazolyl derivative 3a14 for treatment
with levulinic acid and in the presence of 4-(dimethylami-
no)pyridine and of 1-[3-(dimethylamino)propyl]-ethylcar-
bodiimide hydrochloride as coupling agent. Finally, com-
A1, A2A and A3 receptors. The biological results are reported in
Table 1 together with the values of affinity of our lead com-
pound 4a14. Analysis of compounds 4b and 4d in which we
modified the position 9 through introduction of a Cl or an
OCH3 group in para of the phenyl ring led to products with A1
affinity and selectivity comparable to that of lead 4a (Ki =
0.244 μM and 0.233 μM for 4b and 4d respectively). Introduc-
tion of a NO2 or a NH2 group in the same position afforded
compounds 4c and 5 which had higher affinity (Ki = 0.132 μM
for compound 4c and Ki = 0.105 for 5), but there was loss of
selectivity (Ki = 0.116 μM for A2A) for compound 5. 
The replacement of the phenyl at C-9 of 4a with a 3-
furyl (4e) or with a 3-pyridyl (4f) nucleus was associated
with maintenance of selectivity but with of decrease in af-
finity for the A1 subtype (Ki = 0.886 and 0.750 μM respec-
tively), while elimination of the phenyl group (compound
4g) resulted in a loss of potency of one order of magnitu-
de (Ki = 2.48 μM) compared to 4a.
The introduction at position 6 of short alkyl chains
(compound 6a-c) or of a functionalized alkyl chain (com-
pound 7) led to inactive (6b,c and 7) or poorly active (6a,
Ki = 0.811) compounds, suggesting that position 6 of sys-
tem has to remain unsubstituted.
Finally compound 10, in which the benzyl group
was shifted from N-3 of pyridazinone to the neighboring
4-position, showed less activity compared to the lead 4a,
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Scheme 1. Synthesis of pyrazolo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-one 4a-f, 5, 6a-c and 7
Regent and conditions: (a) R1CHO, CH3ONa, CH3OH reflux,
1–10 min.; for compound 2g: DMDA, 110 °C, 90 min.; (b)
NH2NH2 · H2O, EtOH, r.t. –50 °C, 1–3 h; (c) CH(OC2H5)3, H2SO4
conc., DMF, r.t., 30 min.; (d) SnCl2, 37% HCl, r.t., 20 h; (e)
(R1CO)2O, H2SO4 conc., r.t., 10 min.; (f) levulinic acid, DMF,
CH2Cl2, DMAP, DECDI, r.t., 6h and then reflux, 20 h.
confirming the results previously reported14 about the es-
sential role played by carbonyl function at position 4.
3. Conc lu sions
In conclusion, the majority of the new tricyclic deri-
vatives shows affinities for A1 subtypes in submicromolar
concentration range (0.105–0.886) and good selectivity
versus other adenosine subtypes. As regards the modifica-
tions at position 9, the most active compounds, 4c and 5,
bearing a 4-NO2-Ph and a 4-NH2-Ph group respectively,
are about one-fold more potent than the lead 4a, while the
worst is the 9-unsubstituted 4g. On the other hand the in-
troduction of substituents at C-6 of the tricyclic scaffold
led from low active to inactive compounds. Further stu-
dies are in progress in order to improve the potency and
selectivity of these A1 subtype ligands.
4. Ex pe ri men tal Sec tion
All melting points were determined on a Büchi ap-
paratus and are uncorrected. 1H-NMR spectra were recor-
ded with an Avance 400 instruments (Bruker Biospin Ver-
sion 002 with SGU). Chemical shifts are reported in ppm,
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using the solvent as internal standard. Extracts were dried
over Na2SO4, and the solvents were removed under redu-
ced pressure. Merck F-254 commercial plates were used
for analytical TLC to follow the course of reaction. Silica
gel 60 (Merck 70-230 mesh) was used for column chro-
matography. Microanalyses were performed with a Per-
Scheme 2. Synthesis of 4-(benzylthio)pyrazolo[1’,5’:1,6]pyrimido[4,5-d]pyridazine 10
Regent and conditions: (a) Lawesson’s
reagent, toluene, 110 °C, 10 h (b) PhCH2Cl,
K2CO3, anhydrous DMF, 110 °C, 1 h.
Table 1. Binding activity at human A1, A2A and A3 adenosine receptors
Comp. R R1 hA1
a,b hA2A
a,c hA3
a,d
4a[14] Ph H 0.252±0.060 45% 6%
4b 4-Cl-Ph H 0.244±0.024 25% 30%
4c 4-NO2-Ph H 0.132±0.013 43% 46%
4d 4-OCH3-Ph H 0.233±0.007 50% 48%
4e 3-Furyl H 0.886±0.085 56% 7%
4f 3-Pyridyl H 0.750±0.055 46% 5%
4g H H 2.480±0.240 30% 39%
5 4-NH2-Ph H 0.105±0.010 0.116±0.033 39%
6a Ph i-C3H7 0.811±0.079 7% 36%
6b Ph n-C3H7 50% 25% 39%
6c Ph n-C4H9 49% 8% 37%
7 Ph -(CH2)2COCH3 45% 9% 50%
10 1.744±0.165 20% 30%
a The binding activity is reported as Ki (μM) or percentage of inhibition at 10 μM; values are
means   ± DS of four separate assay, each performed in triplicate.   b Displacement of
[3H]DPCPX binding in CHO-A1 cells membranes.   c Displacement of [3H]NECA binding in
A2A CHO cells membranes.   
d Displacement of [125I]AB-MECA binding in A3 CHO cells
membranes.
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kin-Elmer 260 elemental analyzer for C, H, and N, and the
results were within ±0.4% of the theoretical values, unless
otherwise stated. Reagents and starting materials were
commercially available.
4. 1. Pre pa ra tion of Com pounds
General Procedures for 2b-f
A mixture of compound 114 (0.6 mmol), the appro-
priate arylaldehyde (1.5 mmol) and CH3ONa (1–2 mmol)
in anhydrous methanol (1–2 mL) was refluxed under stir-
ring for 1–5 min. After cooling, the crude solid was isola-
ted by filtration and recrystallized by ethanol.
6-Benzyl-3-(4-chlorostyryl)-4-(4-fluorophenyl)isoxa-
zolo[3,4-d]pyridazin-7(6H)-one, 2b
Yield = 53%; mp = 217--220 °C (EtOH); 1H-NMR
(CDCl3) δ 5.40 (s, 2H, CH2Ph), 6.75 (d, 1H, CH=CH),
7.30–7.40 (m, 9H, Ar), 7.55 (m, 2H, Ar), 7.65 (m, 3H: 2H,
Ar; H, CH=CH); MS m/z 458 [M+]; Anal. Calcd for
C26H17ClFN3O2: C, 68.20; H, 3.74; N, 9.18. Found C,
68.34; H, 3.75; N, 9.21.
6-Benzyl-4-(4-fluorophenyl)-3-(4-nitrostyryl)isoxazo-
lo[3,4-d]pyridazin-7(6H)-one, 2c
Yield = 73%; mp = 202--205 °C (EtOH); 1H-NMR
(CDCl3) δ 5.40 (s, 2H, CH2Ph), 6.90 (d, 1H, CH=CH),
7.30–7.40 (m, 5H, Ar), 7.45–7.55 (m, 4H, Ar), 7.65 (m,
2H, Ar), 7.70 (d, 1H, CH=CH), 8.25 (d, 2H, Ar); MS m/z
469 [M+]; Anal. Calcd for C26H17FN4O4: C, 66.66; H,
3.66; N, 11.96 Found C, 66.50; H, 3.67; N, 11.92.
6-Benzyl-4-(4-fluorophenyl)-3-(4-methoxystyryl)iso-
xazolo[3,4-d]pyridazin-7(6H)-one, 2d
Yield = 76%; mp = 228--230 °C (EtOH); 1H-NMR
(CDCl3) δ 3.85 (s, 3H, OCH3), 5.40 (s, 2H, CH2Ph), 6.65
(d, 1H, CH=CH), 6.90 (m, 2H, Ar), 7.25–7.45 (m, 9H,
Ar), 7.55 (d, 1H, CH=CH), 7.60 (m, 2H, Ar); MS m/z 454
[M+]; Anal. Calcd for C27H20FN3O3: C, 71.51; H, 4.45; N,
9.27. Found C, 71.34; H, 4.47; N, 9.30.
6-Benzy l -4 - (4 - f luoropheny l ) -3 - [2- ( furan-3 -
yl)vinyl]isoxazolo[3,4-d]pyridazin-7(6H)-one, 2e
Yield = 77%; mp = 219–220 °C dec. (EtOH); 
1H-NMR (CDCl3) δ 5.40 (s, 2H, CH2Ph), 6.30 (m, 1H, Ar),
6.45 (d, 1H, CH=CH), 7.25–7.40 (m, 5H, Ar), 7.45 (m, 1H,
Ar), 7.50–7.60 (m, 5H: 4H, Ar; 1H CH=CH), 7.70 (s, 1H,
Ar); MS m/z 414 [M+]; Anal. Calcd for C24H16FN3O3: C,
69.73; H, 3.90; N, 10.16. Found C, 69.53; H, 3.91; N, 10.20.
6-Benzyl-4-(4-f luorophenyl)-3- [2-(pyridin-3-
yl)vinyl]isoxazolo[3,4-d]pyridazin-7(6H)-one, 2f
Yield = 16%; mp = 130–131 °C dec. (EtOH); 
1H-NMR (CDCl3) δ 5.40 (s, 2H, CH2Ph), 7.00 (d, 1H,
CH=CH), 7.30-7.40 (m, 5H, Ar), 7.55 (m, 2H, Ar), 7.65
(m, 2H, Ar), 7.70 (d, 1H, CH=CH), 7.80 (m, 1H, Ar), 8.10
(m. 1H, Ar), 8.75 (m, 1H, Ar), 8.80 (s, 1H, Ar); MS m/z
425 [M+]; Anal. Calcd for C25H17FN4O2: C, 70.75; H,
4.04; N, 13.20. Found C, 70.95; H, 4.06; N, 13.16.
6-Benzyl-3-(2-dimethylaminovinyl)-4-(4-fluorop-
henyl)isoxazolo[3,4-d]pyridazin-7(6H)-one, 2g
A suspension of 114 (0.6 mmol) in N,N-dimethylfor-
mammide dimethyl acetal (22.5 mmol) was refluxed un-
der stirring 90 min. After cooling the precipitate was reco-
vered by suction.
Yield = 73%; mp = 162–163 °C (EtOH); 1H-NMR
(CDCl3) δ 2.90 (s, 6H, N(CH3)2), 4.75 (d, 1H, CH=CH),
5.35 (s, 2H, CH2Ph), 7.15–7.25 (m, 2H, Ar), 7.30–7.40
(m, 5H, Ar), 7.55 (m, 3H: 1H, Ar; 1H, CH=CH); MS m/z
391 [M+]; Anal. Calcd for C22H19FN4O2: C, 67.68; H,
4.91; N, 14.35. Found C, 67.91; H, 4.89; N, 14.32.
General Procedures for 3b-f
To a suspension of compounds 2b-g (0.45 mmol) in
ethanol (3–3.5 mL), 10–15 mmol of hydrazine hydrate
was added and the mixture was heated at 50–70 °C for
3–4 h. After cooling the suspension was concentrated un-
der vacuum and the solid was recovered by suction and re-
crystallizzed by ethanol.
4-Amino-2-benzyl-5-[5-(4-chlorophenyl)-2H-pyrazol-
3-yl]-6-(4-fluorophenyl)pyridazin-3(2H)-one, 3b
Yield = 62%; mp = 142–143 °C (EtOH); 1H-NMR
(CDCl3) δ 5.45 (s, 2H, CH2Ph), 5.70 (s, 1H Ar), 6.65
(exch br s, 2H, NH2), 7.05 (m, 3H, Ar), 7.30–7.40 (m, 8H,
Ar), 7.50 (m, 2H, Ar), 8.20 (exch br s, 1H, NH); MS m/z
472 [M+]; Anal. Calcd for C26H19ClFN5O: C, 66.17; H,
4.06; N, 14.84. Found C, 66.32; H, 4.07; N, 14.81.
4-Amino-2-benzyl-6-(4-fluorophenyl)-5-[5-(4-nitrop-
henyl)-2H-pyrazol-3-yl]pyridazin-3(2H)-one, 3c
Yield = 72%; mp = 205–207 °C dec. (EtOH); 
1H-NMR (CDCl3) δ 5.45 (s, 2H, CH2Ph), 6.15 (s, 1H, Ar),
6.35 (exch br s, 2H, NH2), 7.00–7.10 (m, 2H, Ar),
7.30–7.40 (m, 5H, Ar), 7.55 (d, 2H, Ar), 7.70 (d, 2H, Ar),
8.20 (exch br s, 1H, NH), 8.30 (d, 2H, Ar); MS m/z 483
[M+]; Anal. Calcd for C26H19FN6O3: C, 64.73; H, 3.97; N,
17.42. Found C, 64.87; H, 3.97; N, 17.47.
4-Amino-2-benzyl-6-(4-fluorophenyl)-5-[5-(4-met-
hoxyphenyl)-2H-pyrazol-3-yl]pyridazin-3(2H)-one, 3d
Yield = 30%; mp = 168–170 °C (EtOH); 1H-NMR
(CDCl3) δ 3.85 (s, 3H, CH3O), 5.40 (s, 2H, CH2Ph), 6.05
(s, 1H Ar), 6.40 (exch br s, 2H, NH2), 6.95–7.05 (m, 4H,
Ar), 7.30–7.40 (m, 5H, Ar), 7.55 (m, 2H, Ar), 7.65 (m,
2H, Ar), 8.20 (exch br s, 1H, NH); MS m/z 468 [M+];
Anal. Calcd for C27H22FN5O2: C, 69.37; H, 4.74; N,
14.98. Found C, 69.56; H, 4.75; N, 14.94.
4-Amino-2-benzyl-6-(4-fluorophenyl)-5-[(5-furan-3-
yl)-2H-pyrazol-3-yl]pyridazin-3(2H)-one, 3e
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Yield = 38%; mp = 132–135 °C dec. (EtOH); 
1H-NMR (CDCl3) δ 5.40 (s, 2H, CH2Ph), 5.90 (s, 1H Ar),
6.30 (exch br s, 2H, NH2), 6.75 (m, 1H, Ar), 6.95–7.05 (m,
2H, Ar), 7.30–7.40 (m, 4H, Ar), 7.45 (m, 1H, Ar), 7.50 (m,
3H, Ar), 7.90 (s. 1H, Ar), 8.10 (exch br s, 1H, NH); MS m/z
428 [M+]; Anal. Calcd for C24H18FN5O2: C, 67.44; H, 4.24;
N, 16.38. Found C, 67.55; H, 4.24; N, 14.30.
4-Amino-2-benzyl-6-(4-fluorophenyl)-5-[(5-pyridin-3-
yl-2H-pyrazol-3-yl)]pyridazin-3(2H)-one, 3f
Yield = 42%; mp = 238–240 °C (EtOH); 1H-NMR
(CDCl3) δ 5.40 (s, 2H, CH2Ph), 6.20 (s, 1H, Ar), 6.40
(exch br s, 2H, NH2), 7.30–7.40 (m, 6H, Ar), 7.50–7.60
(m, 3H, Ar), 7.90 (m, 1H, Ar), 8.10 (exch br s, 1H, NH),
8.40 (m, 1H, Ar), 8.60 (m. 1H, Ar), 9.75 (s, 1H, Ar); MS
m/z 439 [M+]; Anal. Calcd for C25H19FN6O: C, 68.48; H,
4.37; N, 19.17. Found C, 68.34; H, 4.36; N, 19.13.
4-Amino-2-benzyl-6-(4-fluorophenyl)-5-(2H-pyrazol-
3-yl)pyridazin-3(2H)-one, 3g
Yield = 70%; mp = 190–192 °C (EtOH); 1H-NMR
(CDCl3) δ 5.40 (s, 2H, CH2Ph), 5.65 (m, 1H, Ar), 6.50
(exch br s, 2H, NH2), 7.00 (m, 2H, Ar), 7.25-7.40 (m, 5H,
Ar), 7.45-7.55 (m, 3H, Ar), 8.10 (exch br s, 1H, NH); MS
m/z 362 [M+]; Anal. Calcd for C20H16FN5O: C, 66.47; H,
4.46; N, 19.38. Found C, 66.62; H, 4.45; N, 19.33.
General Procedures for 4b-f
A mixture of compounds 3b-g (0.21 mmol), triethy-
lorthoformate (18 mmol) and a catalytic amount of con-
centrated sulfuric acid in anhydrous DMF (0.5–1 mL) was
stirred at room temperature for 20–30 min. The suspen-
sion was cooled and the precipitate was recovered by suc-
tion and purified by crystallization from ethanol.
3-Benzyl-9-(4-chlorophenyl)-1-(4-fluorophenyl)pyra-
zolo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-one, 4b
Yield = 68%; mp = 246–248 °C dec (EtOH); 
1H-NMR (CDCl3) δ 5.55 (s, 2H, CH2Ph), 6.10 (s, 1H, Ar),
7.30–7.50 (m, 7H, Ar), 7.50–7.60 (m, 4H, Ar), 7.70 (m,
2H, Ar), 9.45 (s, 1H, Ar); MS m/z 482 [M+]; Anal. Calcd
for C27H17ClFN5O: C, 67.29; H, 3.56; N, 14.53. Found C,
67.48; H, 3.56; N, 14.58.
3-Benzyl-1-(4-fluorophenyl)-9-(4-nitrophenyl)pyrazo-
lo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-one, 4c
Yield = 69%; mp = 250–253 °C dec (EtOH); 
1H-NMR (CDCl3) δ 5.50 (s, 2H, CH2Ph), 6.20 (s, 1H, Ar),
7.30–7.40 (m, 5H, Ar), 7.50–7.60 (m, 4H, Ar), 7.95 (d,
2H, Ar), 8.35 (d, 2H, Ar), 9.45 (s, 1H, Ar); MS m/z 493
[M+]; Anal. Calcd for C27H17FN6O3: C, 65.85; H, 3.48; N,
17.07. Found C, 65.66; H, 3.48; N, 17.01.
3-Benzyl-1-(4-fluorophenyl)-9-(4-methoxyphenyl)
pyrazolo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-
one, 4d
Yield = 96%; mp = 165–168 °C dec (THF); 
1H-NMR (CDCl3) δ 3.90 (s, 3H, OCH3), 5.55 (s, 2H,
CH2Ph), 6.05 (s, 1H, Ar), 6.95 (d, 2H, Ar), 7.30–7.40 (m,
5H, Ar), 7.50–7.60 (m, 4H, Ar), 7.70 (d, 2H, Ar), 9.40 (s,
1H, Ar); MS m/z 478 [M+]; Anal. Calcd for C28H20FN5O2:
C, 70.43; H, 4.22; N, 14.67. Found C, 70.19; H, 4.23; N,
14.70.
3-Benzyl-1-(4-fluorophenyl)-9-(furan-3-yl)pyrazo-
lo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-one, 4e
Yield = 55%; mp = 219–220 °C (EtOH); 1H-NMR
(CDCl3) δ 5.55 (s, 2H, CH2Ph), 5.90 (s, 1H, Ar), 6.75 (m,
1H, Ar), 7.30–7.40 (m, 5H, Ar), 7.50–7.60 (m, 4H, Ar),
7.70 (m, 1H, Ar), 7.85 (s, 1H, Ar), 9.40 (s, 1H, Ar); MS
m/z 438 [M+]; Anal. Calcd for C25H16FN5O2: C, 68.64; H,
3.69; N, 16.01. Found C, 68.81; H, 3.70; N, 16.05.
3-Benzyl-1-(4-fluorophenyl)-9-(pyridin-3-yl)pyrazo-
lo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-one, 4f
Yield = 61%; mp = 200–203 °C dec. (EtOH); 
1H-NMR (CDCl3) δ 5.55 (s, 2H, CH2Ph), 6.35 (s, 1H, Ar),
7.30–7.40 (m, 5H, Ar), 7.50–7.60 (m, 4H, Ar), 8.10 (m,
1H, Ar), 8.80 (m, 1H, Ar), 9.00 (m, 1H, Ar), 9.30 (s, 1H,
Ar), 9.50 (s, 1H, Ar); MS m/z 449 [M+]; Anal. Calcd for
C26H17FN6O: C, 69.63; H, 3.82; N, 18.74. Found C,
69.80; H, 3.81; N, 18.79.
3-Benzyl-1-(4-fluorophenyl)pyrazolo[1’,5’:1,6]pyrimi-
do[4,5-d]pyridazin-4(3H)-one, 4g
Yield = 81%; mp = 250–252 °C (EtOH); 1H-NMR
(CDCl3) δ 5.55 (s, 2H, CH2Ph), 5.85 (m, 1H, Ar), 7.20–
7.40 (m, 5H, Ar), 7.50–7.60 (m, 4H, Ar), 8.05 (m, 1H, Ar),
9.45 (s, 1H, Ar); MS m/z 372 [M+]; Anal. Calcd for
C21H14FN5O: C, 67.92; H, 3.80; N, 18.86. Found C,
67.76; H, 3.81; N, 18.89.
9-(4-Aminophenyl)-3-benzyl-1-(4-fluorophenyl)pyra-
zolo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-one, 5
To a solution of 4c (0.21 mmol) in 37% HCl (1 mL),
a solution of SnCl2 (1.03 mmol) in 37% HCl (0.5–1 mL)
was slowly added. The mixture was stirred at room tempe-
rature for 20 h. Water was then added and the mixture was
neutralized with 6N NaOH. The suspension was extracted
with CH2Cl2 (3 × 15 mL) and the solvent was evaporated
in vacuo affording a residue oil which was purified by co-
lumn chromatography using CH2Cl2/CH3OH as eluent.
Yield = 29%; mp = >300 °C (EtOH); 1H-NMR
(CDCl3) δ 5.55 (s, 2H, CH2Ph), 6.10 (s, 1H, Ar), 6.65 (exch
br s, 2H, NH2), 7.20 (d, 2H, Ar), 7.30–7.40 (m, 4H, Ar),
7.50–7.60 (m, 5H, Ar), 7.75 (d, 2H, Ar), 9.40 (s, 1H, Ar);
MS m/z 463 [M+]; Anal. Calcd for C27H19FN6O: C, 70.12;
H, 4.14; N, 18.17. Found C, 70.31; H, 4.14; N, 18.12.
General Procedures for 6a-c
A mixture of 3a14(0.14 mmol), the appropriate
anhydride (4–9 mmol) and a catalytic amount of concen-
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trated sulfuric acid was stirred at room temperature for 10
min. After cooling, the mixture was diluted with cold wa-
ter (10 mL) and neutralized with NaHCO3. Compound 6a
was filtered off and recrystallyzed from ethanol, while for
compounds 6b and 6c the mixture was extracted with
CH2Cl2, the solvent was evaporated under vacuum and the
crude final compounds were purified by crystallization
from ethanol.
3-Benzyl-1-(4-fluorophenyl)-6-isopropyl-9-phenylp-
yrazolo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-one,
6a
Yield = 89%; mp = 217–220 °C (EtOH); 1H-NMR
(CDCl3) δ 1.60 (d, 6H, CH(CH3)2), 4.25 (m, 1H,
CH(CH3)2), 5.50 (s, 2H, CH2Ph), 6.10 (s, 1H, Ar), 7.30–
7.55 (m, 8H, Ar), 7.60–7.70 (m, 4H, Ar), 7.80 (m, 2H,
Ar); MS m/z 490 [M+]; Anal. Calcd for C30H24FN5O: C,
73.60; H, 4.94; N, 14.31. Found C, 73.35; H, 4.93; N,
14.35.
3-Benzyl-1-(4-fluorophenyl)-9-phenyl-6-n-propylp-
yrazolo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-one,
6b
Yield = 74%; mp = 188–191 °C (EtOH); 1H-NMR
(CDCl3) δ 1.15 (t, 3H, CH3(CH2)2), 2.10 (m, 2H,
CH3CH2CH2), 3.55 (t, 2H, CH3CH2CH2), 5.55 (s, 2H,
CH2Ph), 6.10 (s, 1H, Ar), 7.30–7.50 (m, 8H, Ar), 7.60 (m,
4H, Ar), 7.80 (m, 2H, Ar); MS m/z 490 [M+]; Anal. Calcd
for C30H24FN5O: C, 73.60; H, 4.94; N, 14.31. Found C,
73.38; H, 4.94; N, 14.28.
3-Benzyl-6-butyl-1-(4-fluorophenyl)-9-phenylpyrazo-
lo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-4(3H)-one, 6c
Yield = 87%; mp = 190–192 °C (EtOH); 1H-NMR
(CDCl3) δ 1.05 (t, 3H, CH3(CH2)3), 1.50–1.60 (m, 2H,
CH3CH2(CH2)2), 2.00–2.10 (m, 2H, CH3CH2CH2CH2),
3.50–3.60 (t, 2H, CH3CH2CH2CH2), 5.55 (s, 2H, CH2Ph),
6.10 (s, 1H, Ar), 7.30–7.50 (m, 8H, Ar), 7.60–7.80 (m, 6H,
Ar); MS m/z 504 [M+]; Anal. Calcd for C31H26FN5O: C,
73.94; H, 5.20; N, 13.91. Found C, 73.77; H, 5.21; N, 13.95.
3-Benzyl-1-(4-fluorophenyl)-6-(3-oxobutyl)-9-
phenylpyrazolo[1’,5’:1,6]pyrimido[4,5-d]pyridazin-
4(3H)-one, 7
A mixture of 3a14(0.27 mmol), 0.58 mmol of levuli-
nic acid, 0.41 mmol of 4-(dimethylamino)pyridine and
0.48 mmol of 1-[3-(dimethylamino)propyl]-ethylcarbo-
diimide hydocloride in anhydrous CH2Cl2 (10.4 mL) and
anhydrous DMF (1 mL), was refluxed for 20 h. After coo-
ling CH2Cl2 was added (15 mL) and the organic layer was
washed with 2N HCl and with 2N NaOH in turn. Evapo-
ration in vacuum afforded the final compound 7 which
was purified by column chromatography using CH2Cl2/
CH3OH 9.5:0.5 as eluent.
Yield = 15%; mp = 220–222 °C dec. (EtOH); 
1H-NMR (CDCl3) δ 2.40 (s, 3H, CH3CO), 3.35 (t, 2H,
COCH2CH2), 3.80 (t, 2H, COCH2CH2), 5.50 (s, 2H,
CH2Ph), 6.10 (s, 1H, Ar), 7.30–7.40 (m, 5H, Ar), 7.40–
7.50 (m, 3H, Ar), 7.55–7.65 (m, 4H, Ar), 7.80 (m, 2H,
Ar); MS m/z 518 [M+]; Anal. Calcd for C31H24FN5O2: C,
71.94; H, 4.67; N, 13.53. Found C, 72.18; H, 4.67; N,
13.50.
1-(4-fluorophenyl)-9-phenylpyrazolo[1’,5’:1,6]pyrimi-
do[4,5-d]pyridazin-4(3H)-thione, 9
A mixture of 814 (0.25 mmol) and Lawesson’s rea-
gent (1.19 mmol) in toluene (4.8 mL) was heated at 110
°C for 10 h. After cooling, the precipitate was recovered
by suction.
Yield = 54%; mp = 209–210 °C dec. (EtOH); 1H-
NMR (CDCl3) δ 6.05 (s, 1H, Ar), 7.00 (m, 3H, Ar), 7.40–
7.80 (m, 6H, Ar), 9.80 (s, 1H, Ar), 15.00 (exch br s, 1H,
NH); MS m/z 374 [M+]; Anal. Calcd for C20H12FN5S: C,
64.33; H, 3.24; N, 18.76. Found C, 64.13; H, 3.25; N,
18.79.
4-Benzylthio-1-(4-fluorophenyl)-9-phenylpyrazo-
lo[1’,5’:1,6]pyrimido[4,5-d]pyridazina, 10
A mixture of compound 9 (0.21 mmol), K2CO3
(0.66 mmol) and 0.61 mmol of benzyl chloride in anhy-
drous DMF (1.6 mL) was heated under stirring at 110 °C
for 1 h. After cooling, cold water was added and the preci-
pitate was isolated by filtration.
Yield = 30%; mp = 281–282 °C (Ethyl acetate); 
1H-NMR (CDCl3) δ 4.70 (s, 2H, CH2S), 6.30 (s, 1H, Ar),
7.25–7.40 (m, 3H, Ar), 7.40–7.60 (m, 7H, Ar), 7.70–7.90
(m, 4H, Ar), 9.90 (s, 1H, Ar); MS m/z 464 [M+]; Anal.
Calcd for C27H18FN5S: C, 69.96; H, 3.91; N, 15.11. Found
C, 69.75; H, 3.90; N, 15.15 .
4. 2. Ade no si ne Re cep tor Bin ding As say17–19
The binding activity of each compound towards
adenosine receptor subtypes was calculated by competi-
tion binding experiments. To determine the affinities of
the new compounds toward human A1, A2A, and A3 ARs
we evaluated the ability of different compound concentra-
tions to displace [3H]8-cyclopentyl-1,3-dipropylxanthine
([3H]DPCPX, for CHO-A1), [3H]5 -N-ethylcarboxami-
deadenosine ([3H]NECA, for CHO A2A), or [125I]4-ami-
nobenzyl-5 -N-methylcarboxamidoadenosine ([125I]AB-
MECA, for CHO-A3) binding from transfected CHO
cells. Data analysis and graphic presentation were con-
ducted using the non-linear multipurpose curve-fitting
computer program Graph-Pad Prism (GraphPad, San Die-
go, CA). Data analysis allowed to obtain the competition
curve of each compound and to calculate its affinity to-
wards a single population of receptors expressed as Ki va-
lue. For the compounds that at 10 μM concentration sho-
wed an inhibitory effect on radioligand binding lower that
60%, the competition curve was not performed and the re-
sults were expressed as % inhibition at 10 μM.
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Human A1 Adenosine Receptors. Aliquots of cell
membranes (30 μg proteins) obtained from A1CHO cells
were incubated at 25 °C for 180 min in 500 μL of buffer
(50 mM Tris-HCl, 2 mM MgCl2, and 2 units/mL ADA, p-
H 7.4) containing [3H]DPCPX (3 nM) and six different
concentrations of the compounds. Non-specific binding
was determined in the presence of 50 μM R-PIA20 The
dissociation constant (Kd) of [3H]DPCPX in A1 CHO cell
membranes was 3 nM.
Human A2A Adenosine Receptors. Aliquots of cell
membranes (30 μg proteins) were incubated at 25 °C for
180 min in 500 μL of buffer (50mM Tris-HCl, 2 mM Mg-
Cl2, and 2 units/mL ADA, pH 7.4) in the presence of 20 n-
M of [3H]NECA and six different concentrations of the
synthesized compounds. Non-specific binding was deter-
mined in the presence of 100 μM R-PIA20. The dissocia-
tion constant (Kd) of [3H]NECA in A2A CHO cell mem-
branes was 30 nM.
Human A3 Adenosine Receptors. Aliquots of cell
membranes (20 μg proteins) were incubated at 25 °C for
90 min in 100 μL of buffer (50mM Tris-HCl, 10mM Mg-
Cl2, 1mM EDTA, and 2 units/mL ADA, pH 7.4) in the
presence of 0.14 nM [125I]AB-MECA and six different
concentrations of the synthesized compounds. Non-speci-
fic binding was determined in the presence of 50 μM 
R-PIA20. The dissociation constant (Kd) of [125I]
AB-MECA in A3 CHO cell membranes was 1.4 nM.
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Povzetek
^lanek poro~a o sintezi in biolo{kem ovrednotenju nove serije pirazolo[1’,5’:1,6]pirimido[4,5-d]piridazin-4(3H)-onov
kot ligandov ~love{kega A1 adenozinskega receptorja. Tricikli~no ogrodje je bilo spremenjeno na polo`ajih 6 in 9 z
uvedbo majhnih alkilnih verig in substituiranih fenilov. 
Najbolj zanimive spojine so pokazale Ki za A1 v submikromolarnem obmo~ju (0.105–0.244 μM). Najzanimivej{i del
(spojina 4c) je pokazal znatno afiniteto za A1 (Ki = 0.132 μM), skupaj z dobro selektivnostjo za A2A (43 % inhibicije pri
10 μM) in A3 (46 % inhibicije pri 10 μM).
